Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW5421A/DW5421B combination therapy in hypercholesterolemia or mixed dyslipidemia
NCT07444762Phase 3Completed
- Sponsor
- Daewon Pharm
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ezetimibe in hypercholesterolemia, mixed dyslipidemia, sponsored by Daewon Pharm. Started Apr 2025; status: completed.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT07444762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444762.